TXMD
TherapeuticsMD, Inc.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- X Jul 31 Short interest falls 32.5% to 29.1K
Signal stack
Where each data set points today.
- InstitutionsBULLISH
Q2 2026: 6 added (0 new), 0 trimmed or exited.
- TrendDOWNTREND
14% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| CITADEL ADVISORS LLC | ADD | $190.3K |
| DIMENSIONAL FUND ADVISORS LP | ADD | $43.6K |
| OSAIC HOLDINGS, INC. | DOUBLED | $33.6K |
| UBS Group AG | DOUBLED | $10.3K |
| ROYAL BANK OF CANADA | DOUBLED | $1.0K |
| Farther Finance Advisors, LLC | ADD | $86.00 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | $295.3K |
| UBS Group AG | TRIM | $669.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action Aug 2023| Date | Firm | Rating |
|---|---|---|
| Aug 17, 2023 | Cantor Fitzgerald REITERATE | Neutral |
| Jul 13, 2022 | Cantor Fitzgerald REITERATE | Neutral |
| Jun 7, 2022 | HC Wainwright & Co. DOWNGRADE | Neutral |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Short side
FINRA· Oct 15, 2026SecBot reports
4 filings · 0 bullish · 2 bearish · 1 mixed · 1 neutral- BEARISH 8-KAug 11, 2026
TherapeuticsMD reported Q2 2026 results showing declining license revenue ($869K vs $952K YoY) and…
The declining royalty stream and shrinking cash base ($9.2M) against a $24M market cap suggest limited time for a strategic transaction. Monitor for any announcement of a sale, merger, or asset…
- NEUTRAL 8-KMay 12, 2026
TherapeuticsMD reported Q1 2026 results: net income from continuing operations of $103K vs a net…
The strategic alternatives review is the primary catalyst — a sale or merger could unlock value above the $23M market cap, but there is no timeline and the process could yield nothing. Monitor for…
- BEARISH 10-K/AMar 31, 2026
This is an amended 10-K filing that corrects minor printer errors in the original filing. The…
Monitor the resolution of the Mayne Pharma litigation over net working capital adjustments, as an adverse outcome could significantly impact the company's already limited cash reserves. The going…
- MIXED 8-KMar 30, 2026
TherapeuticsMD reported full-year 2025 financial results showing improved net loss of $(0.7)M…
Monitor for updates on strategic alternatives, as the company continues exploring potential transactions. The narrowing loss and revenue growth provide some stability, but the lack of a timeline…
All TXMD filing & press-release reports (4)
- 8-K reportAug 11, 2026
- 8-K reportMay 12, 2026
- 8-K reportMar 30, 2026
- 10-K/A reportMar 31, 2026